Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01770145 · ClinicalTrials.gov registry record · Phase 4
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
A Phase 4 study, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
NCT01770145 is a Phase 4 study that has completed, run by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals. The registered enrollment target is 127 participants.
The verdict
NCT01770145, a Phase 4 study, has completed, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
Study Summary
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
Interventions
- DRUG APOKYN
- DRUG L-dopa
- DRUG Trimethobenzamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01770145
The ClinicalTrials.gov registry entry for NCT01770145 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which APOKYN is the first listed.
NCT01770145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01770145 about?
NCT01770145 is a clinical study titled "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)". This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
What is the current status of trial NCT01770145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2012-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01770145?
The interventions under investigation include: APOKYN (DRUG), L-dopa (DRUG), Trimethobenzamide (DRUG).
Who is sponsoring clinical trial NCT01770145?
This trial is sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.